Pratteln, Switzerland, March 27, 2024 “ Santhera Pharmaceuticals (SIX: SANN) announces that the China National Medical Products Administration (NMPA) has accepted for priority review the new drug...
Santhera™s Partner Catalyst Launches AGAMREE® (Vamorolone) in the United States
CORAL GABLES, Fla., Feb. 21, 2024 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. (Catalyst or Company) (Nasdaq: CPRX), a commercial-stage, patient-centric biopharmaceutical company focused...
Results from 112 patients with DMD who completed the study confirm maintenance of efficacy and benefits in safety and tolerability of treatment with vamorolone over 48 weeks AGAMREE® has shown safety...
Santhera Launches AGAMREE in Germany as First Market for DMD
Santhera Receives Approval for AGAMREE as a Treatment for DMD
Santhera’s Agamree gains EU approval for Duchenne muscular dystrophy
Santhera`s drug gets US FDA nod for rare muscular dystrophy
Ad hoc announcement pursuant to Art. 53 LR Committee for Medicinal Products for Human Use (CHMP) issues positive opinion for AGAMREE® (vamorolone) for the treatment Duchenne muscular dystrophy (DMD)...
Vamorolone is a Promising Best-In-Class Dissociative Anti-Inflammatory Steroid Treatment for Duchenne Muscular Dystrophy Synergistic Novel Asset Leverages Catalyst's Expertise and Bolsters...